Uvadex, 20 micrograms/ml, solution for blood fraction modification
Methoxsalen
The medicine called Uvadex, 20 micrograms/ml, is a solution for modifying blood fractions.
Methoxsalen is a medicine that changes the way the body reacts to light, which becomes active after
exposure to ultraviolet radiation (UV).
Cutaneous T-cell lymphoma (CTCL) is a blood disease that causes abnormal growth of cells that affect
the skin. Uvadex is used with the THERAKOS CELLEX photopheresis system to alleviate skin symptoms of CTCL when
other treatments are not effective.
The THERAKOS CELLEX photopheresis system provides the UV radiation needed to activate methoxsalen, which then destroys the diseased white blood cells.
Before starting Uvadex, discuss with your doctor if you:
Uvadex is not intended for use in children, as there is no sufficient experience available for this age group.
Tell your doctor about all medicines you are taking or have recently taken, including those that are available without a prescription, such as paracetamol.
No studies have been conducted to assess the effect of food and drink. Since Uvadex is administered as part of a hospital procedure, the decision to eat or drink during the procedure is at the discretion of the specialist doctor.
If you are pregnant, breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor for advice before using this medicine. Pregnant or breastfeeding women must not be given Uvadex.
If you are sexually active and of childbearing age, you must use effective contraception during treatment with Uvadex, as the active substance, methoxsalen, may harm a child conceived during treatment with Uvadex.
Do not drive or operate machinery immediately after the procedure.
This medicine contains 217 mg of alcohol (ethanol) per 5.6 ml dose, which is equivalent to 3.1 mg/kg body weight per 5.6 ml dose. The amount of alcohol in the 5.6 ml of this medicine is equivalent to less than 6 ml of beer or 3 ml of wine.
The small amount of alcohol in this medicine will not have a noticeable effect.
This medicine contains less than 1 mmol of sodium (23 mg) per dose unit, which means the medicine is considered "sodium-free".
This medicine is always administered by a specialist doctor who can explain what is happening. The doctor will decide how many treatment sessions the patient needs. Most patients receive treatment for two consecutive days, once a month, for six months. After four months, the frequency may be increased to two consecutive days, twice a month, if the doctor considers it necessary.
This medicine is administered as follows:
A doctor who has received specialized training in photopheresis will insert a needle into a vein in the arm, allowing blood to flow into a specially designed device (the THERAKOS CELLEX photopheresis system), which separates red blood cells, white blood cells, and plasma. The red blood cells and most of the plasma will be returned to the patient's circulation during the procedure.
The white blood cells and the remaining plasma will be mixed with a calculated dose of Uvadex, then exposed to UV radiation in the device, and finally returned to the patient's body.
The procedure takes three to four hours from the time the needle is inserted to the time all blood components are returned to the body.
No more than 20 photopheresis sessions can be performed within 6 months.
During the procedure and for 24 hours after, the patient must wear special, wrap-around sunglasses that block UVA radiation to avoid eye damage that can cause cataracts.
After the procedure, avoid sunlight for at least 24 hours, as it can damage the skin, causing sunburn or premature aging of the skin. If the patient must go outside, they should protect their skin with a strong UV filter and wear sunglasses (see above).
This is very unlikely, but if too much of the medicine is given, the patient may need to stay in a darkened room for 24 hours or longer.
Like all medicines, Uvadex can cause side effects, although not everybody gets them.
The following side effects have been reported:
Uncommon
Frequency not known (frequency cannot be estimated from the available data)
If you experience any side effects, including any not listed in this package leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Medicinal Product Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products,
Al. Jerozolimskie 181C,
02-222 Warsaw,
Phone: 22 49 21 301,
Fax: 22 49 21 309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Uvadex is stored in a hospital pharmacy. Do not store above 25°C.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton. The expiry date refers to the last day of the month stated.
Clear, colorless solution.
A 10 ml glass vial with a rubber stopper, in a cardboard box.
Therakos Europe Ltd,
College Business & Technology Park,
Cruiserath, Blanchardstown,
Dublin 15,
Ireland
ecphelp@therakos.com
Penn Pharmaceutical Services Limited,
Units 23 & 24 Tafarnaubach Industrial Estate,
Tredegar, Gwent, Wales, NP22 3AA,
United Kingdom
Therakos EMEA Ltd,
College Business & Technology Park,
Cruiserath Road, Blanchardstown,
Dublin 15,
Ireland
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.